Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
Key Points
Chief Medical Officer Harold Bernstein exercised 15,000 shares, which were sold immediately for a total transaction value of approximately $690,300 on Feb. 2, 2026.
Maze Therapeutics recently hit its one-year anniversary on the market, posting 174% growth over that period.
- 10 stocks we like better than Maze Therapeutics ›
On Feb. 2, 2026, Harold Bernstein, President, R&D & CMO of Maze Therapeutics (NASDAQ:MAZE), exercised 15,000 options and immediately sold the resulting shares in an open-market transaction, fully divesting his direct ownership, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 15,000 |
| Transaction value | ~$690,300 |
| Post-transaction shares (direct) | 0 |
Transaction value based on SEC Form 4 weighted average purchase price ($46.02).
Key questions
- What was the nature and structure of this transaction?
This was a derivative transaction involving the exercise of 15,000 stock options, immediately followed by the open-market sale of the resulting shares. - How does the transaction relate to Bernstein’s available share capacity and recent activity?
This sale exhausted Bernstein’s remaining direct share capacity, following a series of administrative transactions that reduced his holdings from 90,000 shares to 0 over the past year.
Company overview
| Metric | Value |
|---|---|
| Price (as of 2/14/26) | $46.01 |
| Market capitalization | $2.21 billion |
| Net loss (TTM) | $101.46 million |
| 1-year price change | 284.06% |
* 1-year price change calculated using Feb. 14, 2026 as the reference date.
Company snapshot
Maze Therapeutics is a clinical-stage biotechnology company that develops small-molecule precision medicines targeting renal (kidney), cardiovascular, and metabolic diseases, as well as obesity. Its lead candidate medicines include ones that help with kidney disease.
What this transaction means for investors
Bernstein’s sale shouldn’t concern investors, as it was part of a 10b5-1 trading plan that allows insiders to prearrange the purchase or sale of shares. And even though he doesn’t hold any direct shares, he still holds nearly 300,000 stock options after the Feb. 2 sale was conducted.
There have been many instances in which, once a company has its IPO and share prices shoot up following the market debut, they fall back, and the price settles and becomes less volatile for a few months, if not years. But for Maze, after its first four months on the market, the stock posted nine straight months of gains, soaring 158% for the entire year of 2025, just after its IPO on Jan. 31, 2025.
While the stock may eventually experience a brief drawdown amid so much significant bullish momentum, it’s widely considered a strong buy among Wall St analysts and continues to advance in clinical trials for multiple medicines.
Should you buy stock in Maze Therapeutics right now?
Before you buy stock in Maze Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Maze Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $414,554!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,120,663!*
Now, it’s worth noting Stock Advisor’s total average return is 884% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 16, 2026.
Adé Hennis has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
